4.00
前日終値:
$3.77
開ける:
$3.84
24時間の取引高:
343.72K
Relative Volume:
0.60
時価総額:
$207.07M
収益:
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.5038
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
-3.61%
1か月 パフォーマンス:
+14.61%
6か月 パフォーマンス:
-31.15%
1年 パフォーマンス:
-82.80%
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FDMT
4 D Molecular Therapeutics Inc
|
4.00 | 207.07M | 20.72M | -100.84M | -78.56M | -2.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-11-21 | 開始されました | Morgan Stanley | Underweight |
2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-04-15 | 開始されました | Barclays | Overweight |
2024-02-07 | 再開されました | Goldman | Buy |
2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
2022-11-18 | 開始されました | H.C. Wainwright | Buy |
2022-11-15 | アップグレード | Goldman | Neutral → Buy |
2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2022-06-22 | 開始されました | Jefferies | Buy |
2022-01-04 | 開始されました | SVB Leerink | Outperform |
2021-01-05 | 開始されました | BofA Securities | Buy |
2021-01-05 | 開始されました | Evercore ISI | Outperform |
2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com
Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World
Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times
Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World
Analysts Set Expectations for SHLS FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings - Defense World
Analysts Set Expectations for SLNO FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for SPWR FY2026 Earnings - Defense World
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
ProShare Advisors LLC Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Bank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Two Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Tesco (LON:TSCO) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Telsey Advisory Group Forecasts Macy’s’ Q2 Earnings (NYSE:M) - Defense World
D. E. Shaw & Co. Inc. Purchases 12,217 Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World
4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus
4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com
Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance
Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
4 D Molecular Therapeutics Inc (FDMT) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Bizily Scott | Chief Legal Officer |
Sep 16 '24 |
Sale |
16.33 |
500 |
8,165 |
6,781 |
Bizily Scott | Chief Legal Officer |
Aug 19 '24 |
Option Exercise |
6.49 |
500 |
3,245 |
7,281 |
Bizily Scott | Chief Legal Officer |
Aug 19 '24 |
Sale |
15.00 |
500 |
7,500 |
6,781 |
Bizily Scott | Chief Legal Officer |
Jul 16 '24 |
Option Exercise |
7.60 |
1,750 |
13,295 |
8,531 |
Bizily Scott | Chief Legal Officer |
Jul 16 '24 |
Sale |
27.11 |
1,750 |
47,442 |
6,781 |
Bizily Scott | Chief Legal Officer |
Jul 11 '24 |
Option Exercise |
15.78 |
1,996 |
31,497 |
8,777 |
Bizily Scott | Chief Legal Officer |
Jul 11 '24 |
Sale |
25.00 |
1,996 |
49,900 |
6,781 |
Kirn David | Chief Executive Officer |
Jul 10 '24 |
Option Exercise |
14.55 |
12,923 |
188,077 |
1,072,076 |
Kirn David | Chief Executive Officer |
Jul 10 '24 |
Sale |
22.49 |
12,923 |
290,598 |
1,059,153 |
Bizily Scott | Chief Legal Officer |
Jul 01 '24 |
Option Exercise |
7.55 |
4,248 |
32,089 |
5,985 |
大文字化:
|
ボリューム (24 時間):